Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.

Autor: Kim SS; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Chung JR; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Belongia EA; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA., McLean HQ; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA., King JP; Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA., Nowalk MP; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA., Zimmerman RK; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA., Balasubramani GK; University of Pittsburgh Schools of the Health Sciences, Pittsburgh, Pennsylvania, USA., Martin ET; University of Michigan, Ann Arbor, Michigan, USA., Monto AS; University of Michigan, Ann Arbor, Michigan, USA., Lamerato LE; Henry Ford Health System, Detroit, Michigan, USA., Gaglani M; Baylor Scott and White Health.; Texas A&M University College of Medicine, Temple, Texas, USA., Smith ME; Baylor Scott and White Health., Dunnigan KM; Baylor Scott and White Health., Jackson ML; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA., Jackson LA; Kaiser Permanente Washington Health Research Institute, Seattle, Washington, USA., Tenforde MW; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Verani JR; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Kobayashi M; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Schrag SJ; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Patel MM; Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Flannery B; Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2021 Nov 22; Vol. 224 (10), pp. 1694-1698.